Risk assessment and predicting outcomes in patients with depressive symptoms: a review of potential role of peripheral blood based biomarkers
暂无分享,去创建一个
Jonathan Cavanagh | Barbara I. Nicholl | Frances S. Mair | Naveed Sattar | F. Mair | N. Sattar | B. Jani | B. Nicholl | J. Cavanagh | Gary McLean | G. McLean | Bhautesh D. Jani | Sarah J. E. Barry | S. Barry
[1] K. Tansey,et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. , 2014, The American journal of psychiatry.
[2] Katherine E Henson,et al. Risk of Suicide After Cancer Diagnosis in England , 2018, JAMA psychiatry.
[3] J. Flint,et al. The Genetics of Major Depression , 2014, Neuron.
[4] Garth L. Maker,et al. A review of peripheral biomarkers in major depression: The potential of inflammatory and oxidative stress biomarkers , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[5] P. Sienaert,et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables , 2013, Psychological Medicine.
[6] G. Freedman,et al. Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010 , 2013, PLoS medicine.
[7] R. Cohen,et al. Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D). , 2013, Journal of affective disorders.
[8] H. Möller,et al. No role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysis , 2013, Annals of General Psychiatry.
[9] A. Mitchell,et al. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. , 2013, The Lancet. Oncology.
[10] Janet B W Williams. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[11] A. Damjanović,et al. Melancholic and atypical major depression — Connection between cytokines, psychopathology and treatment , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[12] Femke Lamers,et al. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile , 2013, BMC Medicine.
[13] W. Lawson. Autism spectrum conditions: the pathophysiological basis for inattention and the new Diagnostic and Statistical Manual of Mental Disorders (DSM-V) , 2013 .
[14] David Prvulovic,et al. Novel biomarkers in major depression , 2013, Current opinion in psychiatry.
[15] P. Xie,et al. Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation. , 2012, The international journal of neuropsychopharmacology.
[16] J. Ayuso-Mateos,et al. Definitions and factors associated with subthreshold depressive conditions: a systematic review , 2012, BMC Psychiatry.
[17] Peng Xie,et al. Identification and Validation of Urinary Metabolite Biomarkers for Major Depressive Disorder* , 2012, Molecular & Cellular Proteomics.
[18] P. Sachdev,et al. Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: The prospective Sydney Memory and Aging Study , 2012, Psychoneuroendocrinology.
[19] W. Drevets,et al. How Biomarkers Will Change Psychiatry. Part II: Biomarker Selection and Potential Inflammatory Markers of Depression , 2012, Journal of psychiatric practice.
[20] J. Mann,et al. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. , 2012, Archives of general psychiatry.
[21] R. Mergl,et al. Can effects of antidepressants in patients with mild depression be considered as clinically significant? , 2012, Journal of affective disorders.
[22] Peng Xie,et al. Plasma metabonomics as a novel diagnostic approach for major depressive disorder. , 2012, Journal of proteome research.
[23] M. Kubera,et al. Activation of cell-mediated immunity in depression: Association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[24] M. Blackman,et al. Clinical Subtypes of Depression Are Associated with Specific Metabolic Parameters and Circadian Endocrine Profiles in Women: The Power Study , 2012, PloS one.
[25] A. Caspi,et al. Serotonin transporter gene moderates childhood maltreatment's effects on persistent but not single-episode depression: replications and implications for resolving inconsistent results. , 2011, Journal of affective disorders.
[26] J. Hauser,et al. Glucocorticoid receptor polymorphism is associated with major depression and predominance of depression in the course of bipolar disorder. , 2011, Journal of affective disorders.
[27] Ronald S Duman,et al. Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology , 2011, Neuropsychopharmacology.
[28] D. Goldberg,et al. The heterogeneity of “major depression” , 2011, World psychiatry : official journal of the World Psychiatric Association.
[29] J. Pruessner,et al. Allostatic load associations to acute, 3-year and 6-year prospective depressive symptoms in healthy older adults , 2011, Physiology & Behavior.
[30] Florian Kronenberg,et al. Differences between Human Plasma and Serum Metabolite Profiles , 2011, PloS one.
[31] C. Pariante,et al. Glucocorticoids, cytokines and brain abnormalities in depression , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[32] G. Miller,et al. Depression and Hypothalamic-Pituitary-Adrenal Activation: A Quantitative Summary of Four Decades of Research , 2011, Psychosomatic medicine.
[33] N. Wray,et al. Genome-wide association study of major depressive disorder: new results, meta-analysis, and lessons learned , 2010, Molecular Psychiatry.
[34] P. Gean,et al. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. , 2010, Journal of affective disorders.
[35] S. Horvath,et al. Biomarkers to Predict Antidepressant Response , 2010, Current psychiatry reports.
[36] A. Nierenberg,et al. Deficits in Psychological Well‐Being and Quality‐of‐Life in Minor Depression: Implications for DSM‐V , 2010, CNS neuroscience & therapeutics.
[37] J. Davidson. Major depressive disorder treatment guidelines in America and Europe. , 2010, The Journal of clinical psychiatry.
[38] D. Segal. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) , 2010 .
[39] R. DeRubeis,et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. , 2010, JAMA.
[40] A. Mitchell,et al. Clinical diagnosis of depression in primary care: a meta-analysis , 2009, The Lancet.
[41] J. Jokinen,et al. HPA axis hyperactivity and cardiovascular mortality in mood disorder inpatients. , 2009, Journal of affective disorders.
[42] R. McIntyre,et al. Metabolic syndrome and major depressive disorder: Co-occurrence and pathophysiologic overlap , 2009, Current diabetes reports.
[43] F. Holsboer,et al. HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients , 2009, Psychoneuroendocrinology.
[44] N. Sattar,et al. Novel antecedent plasma biomarkers of cardiovascular disease: improved evaluation methods and comparator benchmarks raise the bar , 2008, Current opinion in lipidology.
[45] R. Vermeulen,et al. Reproducibility and Correlations of Multiplex Cytokine Levels in Asymptomatic Persons , 2008, Cancer Epidemiology Biomarkers & Prevention.
[46] Doh-Kwan Kim,et al. Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response , 2008, Psychiatry investigation.
[47] M. Maes. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. , 2008, Neuro endocrinology letters.
[48] M. Pencina,et al. General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.
[49] Z. Fišar,et al. Depression, antidepressants, and peripheral blood components. , 2008, Neuro endocrinology letters.
[50] Blair T. Johnson,et al. Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.
[51] Vikram Patel,et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys , 2007, The Lancet.
[52] L. Egede. Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. , 2007, General hospital psychiatry.
[53] C. Nemeroff,et al. Prevalence and management of treatment-resistant depression. , 2007, The Journal of clinical psychiatry.
[54] P. Cuijpers,et al. Psychological treatments of subthreshold depression: a meta‐analytic review , 2007, Acta psychiatrica Scandinavica.
[55] N. Cook. Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.
[56] M. Thase. Preventing Relapse and Recurrence of Depression: A Brief Review of Therapeutic Options , 2006, CNS Spectrums.
[57] R. Halfens,et al. Predicting inpatient violence using an extended version of the Brøset-Violence-Checklist: instrument development and clinical application , 2006, BMC psychiatry.
[58] I. Katz,et al. Outcomes of Minor and Subsyndromal Depression among Elderly Patients in Primary Care Settings , 2006, Annals of Internal Medicine.
[59] A. Evans,et al. Translating Clinical Research into Clinical Practice: Impact of Using Prediction Rules To Make Decisions , 2006, Annals of Internal Medicine.
[60] A. Burns,et al. Prognosis of late life depression: a three‐year cohort study of outcome and potential predictors , 2006, International journal of geriatric psychiatry.
[61] A. Döring,et al. C-reactive protein, depressed mood, and the prediction of coronary heart disease in initially healthy men: results from the MONICA-KORA Augsburg Cohort Study 1984-1998. , 2005, European heart journal.
[62] R. Sapolsky. Is impaired neurogenesis relevant to the affective symptoms of depression? , 2004, Biological Psychiatry.
[63] A. Tort,et al. Influence of anticoagulants on the measurement of S100B protein in blood. , 2003, Clinical biochemistry.
[64] M. Wiesmann,et al. S100B and response to treatment in major depression: a pilot study , 2003, European Neuropsychopharmacology.
[65] P. Cuijpers,et al. Excess mortality in depression: a meta-analysis of community studies. , 2002, Journal of affective disorders.
[66] Robyn M Leventhal,et al. Severity of Depression and Response to Antidepressants and Placebo: An Analysis of the Food and Drug Administration Database , 2002, Journal of clinical psychopharmacology.
[67] M. Höfler,et al. Prevalence and recognition of depressive syndromes in German primary care settings: poorly recognized and treated? , 2001, International clinical psychopharmacology.
[68] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[69] H. Vedder,et al. Cytokine Production and Treatment Response in Major Depressive Disorder , 2000, Neuropsychopharmacology.
[70] S. Cooper,et al. Plasma norepinephrine and prediction of outcome in major depressive disorder , 1999, Biological Psychiatry.
[71] K. Davis,et al. Increasing public trust and confidence in psychiatric research. , 1999, Biological psychiatry.
[72] J. Alvarez,et al. Plasma serotonin level after 1 day of fluoxetine treatment: a biological predictor for antidepressant response? , 1999, Psychopharmacology.
[73] P. Celada,et al. Relationship between blood serotonergic variables, melancholic traits, and response to antidepressant treatments. , 1998, Journal of clinical psychopharmacology.
[74] Bruce Mcewen,et al. Stress, Adaptation, and Disease: Allostasis and Allostatic Load , 1998, Annals of the New York Academy of Sciences.
[75] C. Katona,et al. The dexamethasone suppression test and treatment outcome in elderly depressed patients participating in a placebo-controlled multicenter trial involving moclobemide and nortriptyline , 1997, Biological Psychiatry.
[76] J. Macher,et al. Effect of antidepressant medication on morning and evening thyroid function tests during a major depressive episode. , 1996, Archives of general psychiatry.
[77] B. McEwen,et al. Stress and the individual. Mechanisms leading to disease. , 1993, Archives of internal medicine.
[78] E. Bosmans,et al. Depression‐related disturbances in mitogen‐induced lymphocyte responses and interleukin‐1β and soluble interleukin‐2 receptor production , 1991, Acta psychiatrica Scandinavica.
[79] R. Renkawitz,et al. The glucocorticoid receptor. , 1991, Biochimica et biophysica acta.
[80] A. Coppen,et al. Total and free tryptophan concentration in the plasma of depressive patients. , 1972, Lancet.
[81] D. F. Drake,et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. , 2013, JAMA psychiatry.
[82] K. Utsumi. [On clinical diagnosis of depression]. , 2012, Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica.
[83] R. DeRubeis,et al. Antidepressant Drug Effects and Depression Severity , 2022 .
[84] D. Barlow. Psychological treatments. , 2004, The American psychologist.
[85] A. Tort,et al. Influence of anticoagulants on the measurement of S100B protein in blood. , 2003, Clinical biochemistry.
[86] L. Grunhaus,et al. The DST as a predictor of outcome in depression: a meta-analysis. , 1993, The American journal of psychiatry.
[87] B. Carroll,et al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. , 1981, Archives of general psychiatry.